Marykathrine Ley
Acute Care · Roseville, CANPI 1306382726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 289 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,974 and has fallen 73.8% since, to $517 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$898
- Viiv Healthcare Company$376
- Takeda Pharmaceuticals U.S.A., Inc.$285
- Amgen$252
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,211100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $1,148 |
| GSK | 54 | $1,126 |
| Boehringer Ingelheim | 40 | $898 |
| Viiv Healthcare Company | 23 | $376 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $285 |
| Amgen | 14 | $252 |
| Baxter Healthcare | 11 | $190 |
| Inspire Medical Systems, Inc. | 1 | $153 |
| United Therapeutics Corporation | 5 | $130 |
| Sanofi | 6 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $122 |
| Mayne Pharma Commercial LLC | 5 | $112 |
| Grifols USA, LLC | 5 | $112 |
| Harmony Biosciences LLC | 4 | $112 |
| Astellas Pharma US Inc | 4 | $90 |
| Electromed, Inc. | 5 | $90 |
| Merck | 4 | $85 |
| Paratek Pharmaceuticals, Inc. | 4 | $79 |
| Advanced Respiratory, Inc | 4 | $76 |
| Shionogi Inc | 3 | $68 |
| Mylan Specialty L.p. | 4 | $64 |
| CSL Behring | 3 | $62 |
| Incyte Corporation | 2 | $55 |
| AbbVie | 2 | $54 |
| Philips North America LLC | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $34 |
| Gilead | 2 | $33 |
| Verona Pharma, Inc. | 1 | $31 |
| Theratechnologies Inc. | 1 | $28 |
| Novartis | 1 | $26 |
| Pfizer | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $14 |
| Bayer | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,226 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $239,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $161,445 |
| Spiriva RespimatTiotropium Bromide | 66 | $59,503 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $29,270 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $22,277 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $16,239 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $15,897 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $14,334 |
| Epinephrine | 40 | $6,695 |
| Arnuity ElliptaFluticasone Furoate | 16 | $6,544 |
| Atrovent HfaIpratropium Bromide | 11 | $5,924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 110 | $3,903 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $2,485 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,971 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $898 | $298,52985 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,126 | $220,840241 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,148 | $45,16773 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Roseville
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.